Be Alert to the Risk of Adverse Cardiovascular Events after COVID-19 Vaccination

Tuo Han, Weidong Ma, Yan Zhang and Congxia Wang

Department of Cardiology, the Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China

Received: July 02, 2021 | Revised: August 02, 2021 | Accepted: August 16, 2021 | Published: August 24, 2021

Abstract

With the global popularization of vaccination against coronavirus disease 2019 (COVID-19), the reports of cases of vaccine-related adverse events are increasing gradually. The most common events are local pain at the injection site and atypical symptoms, such as fever, headache, myalgia, and general discomfort. However, a few people might develop serious cardiovascular complications, such as myocarditis, coronary spasm, and thrombosis. Elderly people and adolescents should be more alert to vaccine-related cardiovascular adverse events due to their underlying chronic comorbidities or compromised immune systems.

According to the National Health Commission of China, as of Aug 14, 2021, inoculations with COVID-19 vaccines in China had exceeded 1.84 billion doses, and the inoculation ratio or coverage is increasing.1 Due to concern with the pandemic of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant, China has initiated vaccination for people >60 years old and adolescents aged between 12 and 17 years old since the middle of July 2021. With the popularization of vaccination, reports of various types of adverse events are increasing, especially the occurrence of cardiovascular events, which should be paid attention to.2 Currently, there is a wide variety of COVID-19 vaccines that have been approved for emergency use or are receiving scrutiny worldwide, which includes mRNA, viral vectors, virus-like particles, polyepitopes, recombinant proteins, attenuated live viruses, and inactivated viruses.3 Among them, the mRNA vaccine is of the most concern, which has been reported can cause local allergic reactions at the injection site and atypical symptoms, such as fever, headache, myalgia, and general discomfort, which occur in approximately 60% of subjects following the second inoculation.4 The Pfizer-BioNTech (BNT162b1) and Moderna COVID-19 vaccines (mRNA-1273) are two of the most widely used mRNA vaccines globally, which enable the delivery of the RNA into host cells to allow the expression of the SARS-CoV-2 S antigen. The vaccines elicit an immune response and produce antibodies that are specific to the SARS-CoV-2 virus to protect against COVID-19.5 The mRNA-based vaccines have some advantages compared with conventional vaccines due to their high potency, the ability for rapid development, and cost-effective production. They actively induce activation of B cell responses and induce the release of cytokines by activating CD8+ and CD4+ T cells.6 However, the physiochemical properties of mRNA might influence its cellular delivery and organ distribution, which causes mild to moderate local and systematic symptoms in most people that have been vaccinated, thus shield a shadow on mRNA vaccine when safety and reliability are concerned.7 Most of the symptoms might be related to the over-production of type I interferons and cytokines in vivo that are promoted by the vaccine.8

Currently, the widely used COVID-19 vaccines in China, BBIBP-CorV and CoronaVac, are inactivated viruses vaccines, which quickly and effectively induce an immune response against SARS-Cov-2. In addition, they might provoke a strong inflammatory response, which leads to severe adverse cardiovascular events.7 Inactivated viruses are attractive due to their ability to present multiple viral proteins for immune recognition. Apart from the S protein, other proteins, such as the N protein, M protein, non-structural proteins, and accessory proteins, could act as potential antigens for SARS-CoV-2.9 This raises concerns about whether these unimportant antigens could alter the immune system. In addition, more attention should be paid to the antibody-dependent enhancement (ADE) of SARS-CoV-2 infection, because many severe patients that have COVID-19 frequently exhibited more robust immunoglobulin G (IgG) responses and increased antibodies titers, which are closely linked with worse clinical outcomes.9,10

Whether these vaccines cause abnormal antibody responses are
currently uncertain and additional research is required to address the potential damage related to SARS-CoV-2 vaccines.

COVID-19 patients have frequent complications with cardio-metabolic diseases, such as hypertension, atherosclerosis, heart failure, and diabetes.\(^{10-12}\) Populations with the previously underlying diseases are at high risk for infection by SARS-CoV-2 and more severe clinical prognosis.\(^{13,14}\) Aging is known to influence vaccine immunity. Serum neutralization and levels of binding IgG or immunoglobulin A (IgA) following the first vaccine dose are often lower than expected, particularly in older participants.\(^{15}\) Of note, sera from participants >80 years old showed lower neutralization potency against the B.1.1.7 (Alpha), B.1.351 (Beta), and P.1. (Gamma) variants and were more prone to lack any neutralization against viruses following the first inoculation and was accompanied by increased biomarkers for myocardial injury.\(^{15}\) The frequency of SARS-CoV-2 spike-specific memory B cells decreased in non-responders after the first dose, and the production of interferon-γ and interleukin-2 by CD4 T cells was suppressed in older participants.\(^{15}\) In addition, approximately 9.7% of patients had COVID-19 combined with diabetes.\(^{15}\) The expression of ACE2 receptor (total and glycosylated form) in diabetes cardiomyocytes was upregulated, which increased the susceptibility to SARS-CoV-2 infiltration by favoring the cellular entry of the virus.\(^{17}\) In addition, hyperglycemic stress attenuated the efficiency of tocilizumab treatment in diabetic and non-diabetic patients.\(^{18}\) Early glycemic control might be a suitable therapeutic option to reduce the poor outcomes in hospitalized COVID-19 patients with or without diabetes.\(^{19}\) The diabetic and hyperglycemic states could confer a reduced response to anti-inflammatory and anti-viral therapies. However, whether there is a similar situation for vaccination in diabetes is remains unclear. Specific measures to boost the vaccine response in the elderly and diabetic populations are warranted.

There are some cases reports on severe adverse events related to the COVID-19 vaccine, such as neuritis, facial nerve palsy, myocarditis, and thrombosis.\(^{20-22}\) Myocarditis is a relatively rare but serious complication of vaccination, which is mostly self-limited but can be life-threatening.\(^{23}\) Recently, reports of vaccine-related myocarditis were mostly related to the mRNA vaccine (Table 1), which lead to unbearable chest pain that occurred soon after inoculation and was accompanied by increased biomarkers for myocardial injury.\(^{20,24-26}\) Cardiac magnetic resonance imaging shows typical myocarditis symptoms, such as regional dysfunction, late gadolinium enhancement, and elevated native T1 and T2.\(^{26}\) Thrombosis with thrombocytopenia syndrome (TTS) is one of the serious vaccine-related complications, which mainly occurs in women within 2 weeks of the ChAdOx1 nCoV-19 or Ad26.COV2.S vaccination.\(^{27}\) Other vaccines appear to be safe and do not appear to have any disproportional reporting of thromboembolic events or thrombocytopenia.\(^{28,29}\) Impaired type I interferon (IFN) activity, which is characterized by a lack of IFN-β and low

Table 1. Summary of cardiovascular adverse reactions and incidence rates after COVID-19 vaccination

<table>
<thead>
<tr>
<th>Authors</th>
<th>Data sources</th>
<th>Vaccines Names</th>
<th>Vaccine Types</th>
<th>Cardiovascular adverse reactions</th>
<th>Incidence Rates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abu Mouch et al.(^ {20})</td>
<td>Case report</td>
<td>BNT162b2 vaccine</td>
<td>mRNA</td>
<td>5 patients presented myocarditis after the second and 1 after the first dose of the vaccine</td>
<td>NA</td>
</tr>
<tr>
<td>Chamling et al.(^ {24})</td>
<td>EudraVigilance</td>
<td>Pfizer-BioNTech and ChAdOx1 nCoV-19 vaccine</td>
<td>mRNA/adenvirus-vectored</td>
<td>309 (18–64 years old) reported cases of myocarditis associated with Pfizer-BioNTech, 19 (65–85 years old) with ChAdOx1 nCoV-19 vaccine</td>
<td>NA</td>
</tr>
<tr>
<td>Deb et al.(^ {25})</td>
<td>VAERS and CDC website</td>
<td>mRNA-1273</td>
<td>mRNA</td>
<td>37 vaccine recipients developed myocarditis related to mRNA-1273 vaccine</td>
<td>NA</td>
</tr>
<tr>
<td>Kim et al.(^ {26})</td>
<td>Case series</td>
<td>2 received mRNA-1273, and 2 received BNT162b2</td>
<td>mRNA</td>
<td>7 patients with acute myocarditis over 3-months which 4 occurred within 5 days of COVID-19 vaccination</td>
<td>NA</td>
</tr>
<tr>
<td>Lai et al.(^ {27})</td>
<td>EudraVigilance</td>
<td>ChAdOx1 nCoV-19 and Ad26.COV2.S vaccines</td>
<td>adenvirus-vectored</td>
<td>169 cases of CVST and 53 cases of splanchnic vein thrombosis following ChAdOx1 nCoV-19 vaccination out of 34 million people</td>
<td>5 per million people for CVST and 1.6 per million for splanchnic vein thrombosis</td>
</tr>
<tr>
<td>Lai et al.(^ {27})</td>
<td>VAERS</td>
<td>Ad26.COV2.S</td>
<td>adenvirus-vectored</td>
<td>6 cases of CVST with thrombocytopenia following the administration of 6.86 million doses</td>
<td>0.87 cases per million doses</td>
</tr>
<tr>
<td>Sessa et al.(^ {28})</td>
<td>VAERS</td>
<td>Pfizer-BioNTech or mRNA-1273 vaccine</td>
<td>mRNA</td>
<td>68 thromboembolic events out of 13.6 million younger women</td>
<td>1 case per 222,951 vaccinated</td>
</tr>
<tr>
<td>Welsh et al.(^ {29})</td>
<td>VAERS</td>
<td>Pfizer-BioNTech or mRNA-1273 vaccine</td>
<td>mRNA</td>
<td>15 cases of thrombocytopenia were identified among 18,841,309 doses of Pfizer-BioNTech Vaccine and 13 cases among 16,260,102 doses of mRNA-1273 vaccine</td>
<td>0.80 per million doses for both vaccines</td>
</tr>
</tbody>
</table>

Note: NA, not available; VAERS, US Vaccine Adverse Events Reporting System; CDC, Centers for Disease Control; CVST, cerebral venous thrombosis.
IFN-α production, and exacerbated inflammatory responses were observed in severe COVID-19 patients. The excessive immune responses that are caused by vaccines might aggravate myocardial ischemia and plaque progression, which results in myocardial injury, and in severe cases might lead to plaque rupture and induce acute myocardial infarction. Due to the incomplete development of the immune system in adolescents, vaccination might lead to secondary myocarditis, cardiomyopathy, arrhythmia, and heart failure. A recent phase I/II clinical trial demonstrated satisfactory safety, tolerability, and immunogenicity of the CoronaVac vaccine in children and adolescents aged 3–17 years, with injection site pain as the most common adverse reaction. However, long-term immunogenicity and safety were not available and need to be tracked carefully. In addition, stress stimuli, such as nervousness during vaccination, could provoke the occurrence of hypertension, myocardial ischemia, and arrhythmia.

Currently, guidelines or statements on the use of COVID-19 vaccines and the prevention of adverse events are increasing. According to the Centers for Disease Control’s guidance, vaccination locations should: (1) ensure that necessary supplies are available to manage anaphylaxis, especially sufficient quantities of epinephrine in prefilled syringes; (2) screen potential vaccine recipients to identify people with contraindications and precautions, especially those with cardiovascular metabolic comorbidities; (3) implement recommended post-vaccination observation periods, either 15 or 30 minutes that depend on each patient’s previous cardiovascular metabolic conditions; and (4) ensure that health care providers can recognize the signs and symptoms of anaphylaxis and other life-threatening events early. These measures should be strictly carried out especially in remote communities. Patients should seek immediate medical care when they developed signs of cardiovascular diseases during vaccination. In addition, rare and serious adverse events after the COVID-19 vaccination highlight the importance of establishing a sound vaccine safety monitoring system. National regulatory authorities should establish formal trans-regional cooperation to promote data sharing on vaccine safety.

Acknowledgments
The opinions expressed here are solely those of the authors, and not of their affiliations.

Funding
Supported by a grant from the National Science Foundation of China (NO.81273878) and Natural Science Foundation of Shaanxi Province (NO.2021JQ-409).

Conflict of interest
The authors declared no conflict of interests.

Author contributions
HT and MWD conceptualized and wrote the manuscript. ZY and WCX were responsible for the critical revision and supervision.

References


